Health regulator authorizes Phase 3 clinical trials in Brazil of new Covid-19 vaccine

The vaccine is jointly developed by Canadian company Medicago and British pharma giant GSK. Phase 3 clinical trials will be conducted in Brazil involving 3.500 volunteers age 18 or older.

RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (Anvisa), on Thursday, April 8, authorized Phase 3 trials in Brazil of one more vaccine against Covid-19. The immunizer is being developed by the biopharmaceutical Medicago R&D Inc. from Canada and the British pharmaceutical giant GlaxoSmithKline (GSK).

The clinical trials to be conducted in Brazil are last stage Phase 3 and will involve 3,500 volunteers over the age of 18.

Participants will receive a single dose of the vaccine or a placebo (inactive substance), to serve as a control group. The determination of who receives the vaccine . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?